IL1-beta receptor antagonist Therapy(Hamlet BioPharma)

N/A

Report date: 2024/03/20 15:14:44

Base Information

Drug NameIL1-beta receptor antagonist Therapy(Hamlet BioPharma)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 beta antagonists
TargetsInterleukin-1 beta
Therapy Area/IndicationsPainCystitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHamlet BioPharma AB
China Registration ClassN/A

Develop Information

Active CompaniesHamlet BioPharma AB
Inactive CompaniesN/A
Active IndicationsPainCystitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A